We posited that functionalizing anti–4-1BB with DBCO (DBCO–anti–4-1BB) would lead to selective targeting of tumor cells and circumvent the targeting of nonmalignant cells, thus substantially reducing its toxicity. This evidence concerns the gene TNFRSF9 and neoplasm.